Literature DB >> 19596890

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.

Elisabetta Spreghini1, Fiorenza Orlando, Alfredo Santinelli, Eleonora Pisa, Cristian Loretelli, Esther Manso, Maria Eleonara Milici, Giorgio Scalise, Francesco Barchiesi.   

Abstract

We investigated the effects of anidulafungin alone and in combination with amphotericin B against Aspergillus fumigatus. Indifference was the only type of interaction observed in vitro. Anidulafungin at 1 and 5 mg/kg of body weight/day, amphotericin B at 1 mg/kg/day, and combination therapy prolonged the survival of mice with invasive aspergillosis. Anidulafungin at 5 mg/kg/day, alone and in combination with amphotericin B, reduced the kidney fungal burden. Overall, the combination was not superior to the most active single drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596890      PMCID: PMC2737837          DOI: 10.1128/AAC.00659-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 3.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 4.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.

Authors:  John R Graybill; Rosie Bocanegra; Gloria M Gonzalez; Laura K Najvar
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

7.  Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

Authors:  Shawn A Messer; Gary J Moet; Jeffrey T Kirby; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

8.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.

Authors:  Dimitrios P Kontoyiannis; Ray Hachem; Russell E Lewis; Gustavo A Rivero; Harrys A Torres; John Thornby; Richard Champlin; Hagop Kantarjian; Gerald P Bodey; Issam I Raad
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

9.  Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.

Authors:  Olena Sivak; Karen Bartlett; Verica Risovic; Eugene Choo; Fawziah Marra; D Scotty Batty; Kishor M Wasan
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

10.  Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.

Authors:  Timothy B Aliff; Peter G Maslak; Joseph G Jurcic; Mark L Heaney; Kathleen N Cathcart; Kent A Sepkowitz; Mark A Weiss
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

View more
  6 in total

Review 1.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Guanpingsheng Luo; Yue Fu; Samuel W French; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

3.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

Review 4.  Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.

Authors:  Effie L Kuti; Joseph L Kuti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

Review 5.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

6.  Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice.

Authors:  Zoltán Palicz; Tamás Gáll; Éva Leiter; Sándor Kollár; Ilona Kovács; Kornél Miszti-Blasius; István Pócsi; László Csernoch; Péter Szentesi
Journal:  Emerg Microbes Infect       Date:  2016-11-09       Impact factor: 7.163

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.